Equities Analysts Offer Predictions for Humana Q4 Earnings

Humana Inc. (NYSE:HUM) – Analysts at Zacks Research dropped their Q4 2025 EPS estimates for Humana in a report released on Wednesday, November 19th. Zacks Research analyst Team now forecasts that the insurance provider will post earnings of ($4.07) per share for the quarter, down from their previous estimate of ($3.36). The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana’s Q1 2026 earnings at $7.98 EPS, Q2 2026 earnings at $4.96 EPS, Q3 2026 earnings at $1.20 EPS, Q4 2026 earnings at ($2.51) EPS, FY2026 earnings at $11.63 EPS, Q1 2027 earnings at $8.89 EPS, Q3 2027 earnings at $2.96 EPS and FY2027 earnings at $17.60 EPS.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating the consensus estimate of $2.95 by $0.29. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm had revenue of $32.65 billion during the quarter, compared to analyst estimates of $31.99 billion. During the same quarter last year, the business posted $4.16 EPS. The company’s revenue for the quarter was up 11.1% on a year-over-year basis.

Several other research firms have also recently weighed in on HUM. Guggenheim reissued a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Wolfe Research lowered their target price on Humana from $313.00 to $300.00 and set an “outperform” rating on the stock in a research note on Thursday. Barclays cut their price target on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating on the stock in a report on Friday, October 3rd. The Goldman Sachs Group initiated coverage on shares of Humana in a report on Tuesday, October 14th. They set a “sell” rating and a $235.00 price objective for the company. Finally, Sanford C. Bernstein lifted their price objective on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus target price of $297.67.

Humana Stock Performance

HUM stock opened at $223.18 on Friday. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm has a market cap of $26.84 billion, a PE ratio of 17.13, a P/E/G ratio of 1.71 and a beta of 0.42. The business has a 50 day moving average of $266.76 and a 200-day moving average of $257.25. Humana has a 12-month low of $206.87 and a 12-month high of $315.35.

Institutional Trading of Humana

A number of hedge funds and other institutional investors have recently made changes to their positions in HUM. Cary Street Partners Investment Advisory LLC boosted its stake in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 46 shares during the period. Elevation Point Wealth Partners LLC purchased a new stake in shares of Humana in the second quarter worth about $32,000. Mather Group LLC. bought a new position in shares of Humana in the third quarter valued at approximately $34,000. Zions Bancorporation National Association UT bought a new position in shares of Humana in the first quarter valued at approximately $37,000. Finally, Private Wealth Management Group LLC grew its stake in Humana by 47.5% during the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 48 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, December 26th. Humana’s dividend payout ratio (DPR) is presently 33.18%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.